课题基金 / 基金详情

Determination of diagnostic molecular profiles for intraduct lesions of the breast.

Determination of diagnostic molecular profiles for intraduct lesions of the breast.
确定乳腺导管内病变的诊断分子谱。
批准号:
nhmrc : 306700
负责人:
A/Pr Rosemary Balleine
金额:
$20.56万
依托单位国家:
澳大利亚
项目类别:
NHMRC Project Grants
财政年份:
2004
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2004-01-01 至 2006-12-31

项目摘要

项目成果

A/Pr Rosemary Balleine的其他基金

相似基金

相关文献

中文摘要
翻译
乳腺癌起源于乳腺导管内的细胞。乳腺癌筛查的引入导致乳腺癌的诊断急剧增加,乳腺癌仅限于这些导管,尚未扩散到周围组织。这被称为“导管原位癌”或DCIS。很明显,DCIS在引起更晚期乳腺癌的倾向上是可变的。然而,目前我们预测特定DCIS的潜在攻击性的能力是有限的。在这项研究中,我们建议开发新的方法来评估DCIS,这将更准确地预测临床行为。一个重要的辅助手段是确保这些方法可以在常规诊断环境中实际应用。该项目目标的实现将有助于诊断为DCIS的患者的治疗计划。它还将提供关于因乳房筛查而诊断出的乳腺癌的重要信息。
英文摘要
Breast cancer originates in cells within breast ducts. The introduction of Breast Screening for breast cancer has led to a dramatic increase in the diagnosis of breast cancer which is confined to these ducts and has not spread to surrounding tissue. This is known as 'ductal carcinoma in situ' or DCIS. It is evident that DCIS is variable in its tendency to give rise to more advanced breast cancer. However, currently our ability to predict the potential agressiveness of a particular DCIS is limited. In this research we are proposing to develop new methods for evaluation of DCIS that will more accurately predict clinical behaviour. An important adjunct is to ensure that these methods can be practically applied in a routine diagnostic setting. Achievement of the aims of this project will assist treatment planning for patients diagnosed with DCIS. It will also provide important information about breast cancers diagnosed as a consequence of breast screening.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A randomised phase III study of radiation doses and fractionation schedules in non-low risk DCIS of the breast
  • 批准号:
    nhmrc : 454390
  • 项目类别:
    NHMRC Project Grants
  • 资助金额:
    $116.77万
  • 财政年份:
    2007
  • 负责人:
    A/Pr Rosemary Balleine
  • 依托单位:
国内基金
海外基金
OBSL1功能缺失导致多指(趾)畸形的分子机制及其临床诊断价值
  • 批准号:
    82372328
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    项盈
  • 依托单位:
HER2特异性双抗原表位识别诊疗一体化探针研制与临床前诊疗效能研究
  • 批准号:
    82372014
  • 项目类别:
    面上项目
  • 资助金额:
    48.00万元
  • 批准年份:
    2023
  • 负责人:
    魏伟军
  • 依托单位: